Coxsackie B3 virus can replicate in cultured human foetal heart cells and is inhibited by interferon
- PMID: 3889351
- DOI: 10.1016/s0022-2828(85)80019-5
Coxsackie B3 virus can replicate in cultured human foetal heart cells and is inhibited by interferon
Abstract
Coxsackie B viruses (types 1 to 5) are the most frequent reported cause of acute viral myocarditis. To study the pathogenesis of the disease at the cellular level, we simulated an infectious situation by infecting cultured human foetal heart cells with Coxsackie B3 (CB3) virus. Successful replication of this virus could be demonstrated by the presence of virus particles inside cultivated foetal myocytes together with high titres of progeny virus of 10(8) plaque-forming units (PFU) per millilitre culture medium. Within 9 h of infection networks of myocytes lost their ability to contract spontaneously followed by disintegration and replacement by overgrowing fibroblasts which survived the infection. These cells produced CB3 virus continuously over several months, indicating carrier state infection of human myocardial fibroblasts. Human fibroblasts interferon (IFN-beta) was found to act as a potent inhibitor of the replication of this virus. Virus yields could be reduced from 1.2 x 1.8 x 10(5) PFU/ml culture medium when human heart cells were incubated with IFN-beta 20 h prior to challenge with a high input multiplicity of 50 PFU of CB3 virus per cell, demonstrating the major protective role of IFN-beta in CB3 viral infection. It thus appear that IFN-beta might become useful as an antiviral agent in the treatment of Coxsackie myocarditis.
Similar articles
-
Cultured human myocardial fibroblasts of pediatric origin: natural human interferon-alpha is more effective than recombinant interferon-alpha 2a in carrier-state coxsackievirus B3 replication.J Mol Cell Cardiol. 1995 Oct;27(10):2199-208. doi: 10.1016/s0022-2828(95)91515-x. J Mol Cell Cardiol. 1995. PMID: 8576936
-
Ameliorating effect of IFN-beta and anti-IFN-beta on coxsackievirus B3-induced myocarditis in mice.J Interferon Res. 1985 Winter;5(1):137-46. doi: 10.1089/jir.1985.5.137. J Interferon Res. 1985. PMID: 2985716
-
Inhibition of coxsackievirus B3 carrier state infection of cultured human myocardial fibroblasts by ribavirin and human natural interferon-alpha.Antiviral Res. 1997 May;34(3):101-11. doi: 10.1016/s0166-3542(97)01028-0. Antiviral Res. 1997. PMID: 9191017
-
Prevention of murine coxsackie B3 viral myocarditis and associated lymphoid organ atrophy with recombinant human leucocyte interferon alpha A/D.Cardiovasc Res. 1988 Oct;22(10):732-8. doi: 10.1093/cvr/22.10.732. Cardiovasc Res. 1988. PMID: 2855719
-
Molecular pathogenesis of enterovirus-induced myocarditis: virus persistence and chronic inflammation.Intervirology. 1993;35(1-4):140-51. doi: 10.1159/000150305. Intervirology. 1993. PMID: 8407241 Review.
Cited by
-
Anti-viral and anti-myocyte antibodies in experimental myocarditis.Springer Semin Immunopathol. 1989;11(1):69-76. doi: 10.1007/BF00197086. Springer Semin Immunopathol. 1989. PMID: 2546264 Review. No abstract available.
-
IFN-β1b induces OAS3 to inhibit EV71 via IFN-β1b/JAK/STAT1 pathway.Virol Sin. 2022 Oct;37(5):676-684. doi: 10.1016/j.virs.2022.07.013. Epub 2022 Aug 5. Virol Sin. 2022. PMID: 35934228 Free PMC article.
-
Mapping of a neutralizing antigenic site of Coxsackievirus B4 by construction of an antigen chimera.J Virol. 1991 Jul;65(7):3475-80. doi: 10.1128/JVI.65.7.3475-3480.1991. J Virol. 1991. PMID: 1645779 Free PMC article.
-
Interferons in enteroviral heart disease: modulation of cytokine expression and antiviral activity.Med Microbiol Immunol. 2004 May;193(2-3):149-54. doi: 10.1007/s00430-003-0200-3. Epub 2003 Sep 12. Med Microbiol Immunol. 2004. PMID: 13680216
-
Immunomodulating therapy in experimental myocarditis.Springer Semin Immunopathol. 1989;11(1):77-88. doi: 10.1007/BF00197087. Springer Semin Immunopathol. 1989. PMID: 2665156 Review. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources